Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
NCT00482053 · Stanford University · PHASE2 · terminated · last registry update 2018-05-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low accrual” | – | Registry record, Stanford University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPIA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-04-29Phase 3 first posted: Merck Sharp & Dohme LLC, Letermovir + Placebo (NCT03930615)
- 2019-04-08Results posted on the registry: Sun Pharmaceutical Industries Limited, cyclosporine + vehicle of OTX-101 (NCT02688556)
- 2019-02-04Phase 3 first posted: JHSPH Center for Clinical Trials, Adalimumab (ADA) + Conventional immunosuppression (CON) (NCT03828019)
- 2018-12-14Results posted on the registry: Sun Pharmaceutical Industries Limited, OTX-101 0.09% (NCT02845674)
- 2018-09-13Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Abacavir sulfate, Lamivudine, and Zidovudine + Lopinavir/Ritonavir (NCT00084149)
- 2018-09-05Phase 3 first posted: Zambon SpA, Liposomal Cyclosporine A + standard of care (NCT03657342)
- 2018-09-04Phase 3 first posted: Zambon SpA, Liposomal Cyclosporine A + Standard of Care (NCT03656926)
- 2018-06-01Results posted on the registry: Medical College of Wisconsin, Hematopoietic Stem Cell Transplant (NCT01998633)
- 2018-05-09Results posted on the registry: Michael Donahoe, Cyclosporine + Placebo (NCT00974142)
- 2018-02-23Phase 3 first posted: Merck Sharp & Dohme LLC, Letermovir + Valganciclovir (NCT03443869)
- 2018-02-09Phase 3 first posted: Eli Lilly and Company, Baricitinib + Placebo (NCT03428100)
- 2017-12-26Results posted on the registry: Medical College of Wisconsin, Hematopoietic Stem Cell Transplantation (NCT00745420)
- 2017-12-04Results posted on the registry: Fred Hutchinson Cancer Center, Cyclosporine + Fludarabine Phosphate (NCT01231412)
- 2017-10-25Results posted on the registry: University of Maryland, Baltimore, Liposomal aerosol cyclosporine (NCT01650545)
- 2017-09-26Phase 3 first posted: Novaliq GmbH, CyclASol topical ocular, eye drops + Vehicle topical ocular, eye drops (NCT03292809)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision